Pipeline
TechnoPhage currently holds a well-balanced and diversified product portfolio addressing key therapeutic areas while simultaneously being agile in meeting the challenges of the rapidly evolving pharmaceutical industry.
Infection
DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III
- Chronic ulcers (TP-102) 54.3%
- Respiratory infection (TP-122) 46.8%
- Urinary tract infection (TP-164) 12.5%
- COVID-19 (TA-201) 8.5%
Neuroscience
DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III
- Alzheimer’s disease (TA-111) 27.2%
- Parkinson’s disease (TZ-113) 41.5%
- Spinal cord injury (TZ-161) 41.5%
- Undisclosed indication (TA-191) 5%
Ophthalmology
DiscoveryPreclinicalIND/CTAPhase IPhase IIPhase III
- Age macular degeneration (TA-111/16) 27.2%
- Undisclosed indication (TA-182) 12.5%


